The effect of recombinant human erythropoietin on the development of retinopathy of prematurity

Nishant Shah, Pushkaraj Jadav, Dominique Jean-Baptiste, Jay Weedon, Lourdes M. Cohen, M. Roger Kim

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In addition to its hematopoietic effects, erythropoietin causes an increased release of endothelin-1 and the stimulation of angiogenesis and thereby it may have possible role in development of retinopathy of prematurity (ROP). Our objective was to determine if an association exists between recombinant human erythropoietin (rhEPO) treatment and the development of ROP. Our case-control study involved 85 very low birthweight infants with birthweights <1500 g born during 2003 and 2004. All the infants were divided into two groups on the basis of whether they got rhEPO or not. The rhEPO was given at the dose of 200 to 250 units/kg/dose three times a week for 10 doses. Further duration of rhEPO therapy was decided on the basis of the clinical response. Ophthalmological examinations were done at the age of 5 to 6 weeks and were repeated 1 to 4 weeks after the first examination according to the severity of the ROP disease during their in-hospital stay. Of 85 infants, 56 (66%) received rhEPO and 29 (34%) did not. In the rhEPO-treated group, 12 infants (21%) had ROP; in the non-rhEPO group, 11 infants (38%) developed ROP. This difference is not statistically significant (odds ratio=2.63; p=0.10). There was no correlation between the use of rhEPO and the stage of ROP (random sample=0.01; p=0.89). There was no significant difference in the incidence of plus, prethreshold, or threshold disease and the treatment required for ROP between the rhEPO-treated and the nontreated group. The study showed there is no significant difference in the incidence and severity of ROP between the rhEPO-treated and nontreated group.

Original languageEnglish (US)
Pages (from-to)67-71
Number of pages5
JournalAmerican Journal of Perinatology
Volume27
Issue number1
DOIs
StatePublished - Jan 26 2010

Fingerprint

Retinopathy of Prematurity
Erythropoietin
Incidence
Endothelin-1
Case-Control Studies
Length of Stay
Therapeutics
Odds Ratio

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Shah, Nishant ; Jadav, Pushkaraj ; Jean-Baptiste, Dominique ; Weedon, Jay ; Cohen, Lourdes M. ; Kim, M. Roger. / The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. In: American Journal of Perinatology. 2010 ; Vol. 27, No. 1. pp. 67-71.
@article{afe83b0acc6b44cd840eb5903a954731,
title = "The effect of recombinant human erythropoietin on the development of retinopathy of prematurity",
abstract = "In addition to its hematopoietic effects, erythropoietin causes an increased release of endothelin-1 and the stimulation of angiogenesis and thereby it may have possible role in development of retinopathy of prematurity (ROP). Our objective was to determine if an association exists between recombinant human erythropoietin (rhEPO) treatment and the development of ROP. Our case-control study involved 85 very low birthweight infants with birthweights <1500 g born during 2003 and 2004. All the infants were divided into two groups on the basis of whether they got rhEPO or not. The rhEPO was given at the dose of 200 to 250 units/kg/dose three times a week for 10 doses. Further duration of rhEPO therapy was decided on the basis of the clinical response. Ophthalmological examinations were done at the age of 5 to 6 weeks and were repeated 1 to 4 weeks after the first examination according to the severity of the ROP disease during their in-hospital stay. Of 85 infants, 56 (66{\%}) received rhEPO and 29 (34{\%}) did not. In the rhEPO-treated group, 12 infants (21{\%}) had ROP; in the non-rhEPO group, 11 infants (38{\%}) developed ROP. This difference is not statistically significant (odds ratio=2.63; p=0.10). There was no correlation between the use of rhEPO and the stage of ROP (random sample=0.01; p=0.89). There was no significant difference in the incidence of plus, prethreshold, or threshold disease and the treatment required for ROP between the rhEPO-treated and the nontreated group. The study showed there is no significant difference in the incidence and severity of ROP between the rhEPO-treated and nontreated group.",
author = "Nishant Shah and Pushkaraj Jadav and Dominique Jean-Baptiste and Jay Weedon and Cohen, {Lourdes M.} and Kim, {M. Roger}",
year = "2010",
month = "1",
day = "26",
doi = "10.1055/s-0029-1224872",
language = "English (US)",
volume = "27",
pages = "67--71",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",
number = "1",

}

The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. / Shah, Nishant; Jadav, Pushkaraj; Jean-Baptiste, Dominique; Weedon, Jay; Cohen, Lourdes M.; Kim, M. Roger.

In: American Journal of Perinatology, Vol. 27, No. 1, 26.01.2010, p. 67-71.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of recombinant human erythropoietin on the development of retinopathy of prematurity

AU - Shah, Nishant

AU - Jadav, Pushkaraj

AU - Jean-Baptiste, Dominique

AU - Weedon, Jay

AU - Cohen, Lourdes M.

AU - Kim, M. Roger

PY - 2010/1/26

Y1 - 2010/1/26

N2 - In addition to its hematopoietic effects, erythropoietin causes an increased release of endothelin-1 and the stimulation of angiogenesis and thereby it may have possible role in development of retinopathy of prematurity (ROP). Our objective was to determine if an association exists between recombinant human erythropoietin (rhEPO) treatment and the development of ROP. Our case-control study involved 85 very low birthweight infants with birthweights <1500 g born during 2003 and 2004. All the infants were divided into two groups on the basis of whether they got rhEPO or not. The rhEPO was given at the dose of 200 to 250 units/kg/dose three times a week for 10 doses. Further duration of rhEPO therapy was decided on the basis of the clinical response. Ophthalmological examinations were done at the age of 5 to 6 weeks and were repeated 1 to 4 weeks after the first examination according to the severity of the ROP disease during their in-hospital stay. Of 85 infants, 56 (66%) received rhEPO and 29 (34%) did not. In the rhEPO-treated group, 12 infants (21%) had ROP; in the non-rhEPO group, 11 infants (38%) developed ROP. This difference is not statistically significant (odds ratio=2.63; p=0.10). There was no correlation between the use of rhEPO and the stage of ROP (random sample=0.01; p=0.89). There was no significant difference in the incidence of plus, prethreshold, or threshold disease and the treatment required for ROP between the rhEPO-treated and the nontreated group. The study showed there is no significant difference in the incidence and severity of ROP between the rhEPO-treated and nontreated group.

AB - In addition to its hematopoietic effects, erythropoietin causes an increased release of endothelin-1 and the stimulation of angiogenesis and thereby it may have possible role in development of retinopathy of prematurity (ROP). Our objective was to determine if an association exists between recombinant human erythropoietin (rhEPO) treatment and the development of ROP. Our case-control study involved 85 very low birthweight infants with birthweights <1500 g born during 2003 and 2004. All the infants were divided into two groups on the basis of whether they got rhEPO or not. The rhEPO was given at the dose of 200 to 250 units/kg/dose three times a week for 10 doses. Further duration of rhEPO therapy was decided on the basis of the clinical response. Ophthalmological examinations were done at the age of 5 to 6 weeks and were repeated 1 to 4 weeks after the first examination according to the severity of the ROP disease during their in-hospital stay. Of 85 infants, 56 (66%) received rhEPO and 29 (34%) did not. In the rhEPO-treated group, 12 infants (21%) had ROP; in the non-rhEPO group, 11 infants (38%) developed ROP. This difference is not statistically significant (odds ratio=2.63; p=0.10). There was no correlation between the use of rhEPO and the stage of ROP (random sample=0.01; p=0.89). There was no significant difference in the incidence of plus, prethreshold, or threshold disease and the treatment required for ROP between the rhEPO-treated and the nontreated group. The study showed there is no significant difference in the incidence and severity of ROP between the rhEPO-treated and nontreated group.

UR - http://www.scopus.com/inward/record.url?scp=74549124890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549124890&partnerID=8YFLogxK

U2 - 10.1055/s-0029-1224872

DO - 10.1055/s-0029-1224872

M3 - Article

C2 - 19565433

AN - SCOPUS:74549124890

VL - 27

SP - 67

EP - 71

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

IS - 1

ER -